Abstract: Objective To explore the clinical efficacy of branch retinal vein occlusion secondary macular edema(BRVO-ME)treated with Ranibizumab intravitreal injection combined with grille laser photocoagulation(GLP). Methods A total of 135(135 eyes)BRVO-ME cases were divided into 3 groups: simple drug group(n=45), simple laser group(n=45), and combined treatment group(n=45). The simple drug group received Ranibizumab intravitreal injection only. The simple laser group received GLP only. The combined treatment group received Ranibizumab intravitreal injection first, and then GLP 1 week after. The best corrected visual acuity(BCVA), central macular thickness(CMT), and intraocular pressure(IOP)of the 3 groups were observed. Results Three months after treatment, BCVA and CMT of all groups were significantly different(P<0.05). The combined treatment group had significantly lower BCVA and CMT than the other 2 groups in postoperative month 1, 2 and 3(P<0.05). During the treatment, no increased IOP was observed(P>0.05). No postoperative infection, vitreous hemorrhage, bacterial endophthalmitis or other adverse reactions occurred. Conclusion Ranibizumab intravitreal injection combined with GLP is safe and effective in the treatment of BRVO-ME, which can reduce the CMT, relieve macular edema, and improve visual acuity.

Key words: Ranibizumab, Grille laser photocoagulation, Branch retinal vein occlusion, Macular edema